Phase I Expansion Study Of Xmt-1536, A Novel Napi2b-Targeting Antibody-Drug Conjugate (Adc): Preliminary Efficacy, Safety, And Biomarker Results In Patients With Previously Treated Metastatic Ovarian Cancer (Oc) Or Non-Small Cell Lung Cancer (Nsclc).
JOURNAL OF CLINICAL ONCOLOGY（2020）
摘要
3549Background: XMT-1536 is a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, broadly expressed in NSCLC and ovarian cancer. XMT-1536 utilizes the Dolaflexin p...
更多查看译文
关键词
lung cancer,metastatic ovarian cancer,b-targeting,antibody-drug,non-small
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要